NCT05168904 2024-02-08A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)Cyclacel Pharmaceuticals, Inc.Phase 1/2 Suspended210 enrolled